Advertisement

Reactions Weekly

, Volume 1748, Issue 1, pp 368–368 | Cite as

Mycophenolate/prednisone/tocilizumab

Various toxicities: 4 case reports
Case report
  • 26 Downloads
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

A case series described four patients (two women and two men) [exact ages at the time of reaction onsets not stated], who developed osteopenia, hypertension, diabetes, osteonecrosis, leucopenia, worsening diabetes, breast cancer, hyperlipidaemia, Cushingoid features or weight gain during treatment with prednisone, mycophenolate or tocilizumab for pulmonary sarcoidosis [not all dosages stated; routes, times to reactions onsets and outcomes not stated].

Patient 1: A woman had a medical history of pulmonary sarcoidosis, hypercalcaemia, mediastinal and hilar lymphadenopathy and interstitial infiltrates (Scadding stage II). She had been receiving prednisone for her progressive respiratory symptoms. However, multiple attempts to taper prednisone below 15 mg/day resulted in recurrent...

Reference

  1. Sharp M, et al. Tocilizumab in sarcoidosis patients failing steroid sparing therapies and anti-TNF agents. Respiratory Medicine: X 1: Feb 2019. Available from: URL: http://doi.org/10.1016/j.yrmex.2019.100004 - USA

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations